At a glance
ClinicalIndex Comparison Record- ✓Bilateral retinoblastoma with at least one eye having Group C or D intraocular disease by International Classification System
- ✓Group C: localized disease with minimal subretinal/vitreous seeding (subretinal fluid ≤1/4 retina, local fine vitreous seeding, subretinal seeding <3 mm from tumor)
- ✓Group D: diffuse disease with significant vitreous/subretinal seeding (massive/diffuse tumors, subretinal fluid up to total retinal detachment, diffuse/massive vitreous disease)
- ✓Prior enucleation of one eye allowed if remaining eye is Group C or D
- ✕Prior chemotherapy
- ✕Concurrent chemotherapy (other than study drugs)
- ✕Prior radiotherapy
- ✕Concurrent radiotherapy (other than study protocol)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm Trial of Systemic And Subtenon Chemotherapy For Groups C And D Intraocular Retinoblastoma
In Brief
A Phase 3 clinical trial evaluating liposomal vincristine sulfate, cryosurgery, and 4 other interventions for Intraocular Retinoblastoma. Completed, enrolled 30 participants across 11 sites.
Detailed Summary
Phase III trial to determine the effectiveness of combining systemic chemotherapy and subtenon carboplatin with ophthalmic therapy in treating children who have intraocular retinoblastoma. Drugs used in chemotherapy, such as vincristine, carboplatin, and etoposide, work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether systemic chemotherapy and subtenon (under the conjunctiva of the eye) carboplatin combined with ophthalmic therapy is effective in treating intraocular (within the eyeball) retinoblastoma.
Study Details
Timeline
Interventions
Given IV
Application of extreme cold to destroy abnormal or diseased tissue.
Surgery using a laser (instead of a scalpel) to cut tissue
Given IV
Given IV
Given subcutaneously